Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.
作者信息
Claassens Eva L, Ploumen Roxanne A W, van Nijnatten Thiemo J A, Smidt Marjolein L
机构信息
Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
出版信息
Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.
Abstract
摘要
相似文献
1
Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.
Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.
2
Addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC.
Breast. 2025 Jun;81:104466. doi: 10.1016/j.breast.2025.104466. Epub 2025 Apr 4.
3
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.
4
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
5
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.
6
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
Breast Cancer Res Treat. 2018 Nov;172(2):437-444. doi: 10.1007/s10549-018-4928-2. Epub 2018 Aug 21.
7
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
8
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
9
Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Front Oncol. 2021 Nov 29;11:657634. doi: 10.3389/fonc.2021.657634. eCollection 2021.
10
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
Br J Cancer. 2006 Feb 13;94(3):358-62. doi: 10.1038/sj.bjc.6602950.
本文引用的文献
1
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
2
Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
Eur Radiol. 2023 Aug;33(8):5423-5435. doi: 10.1007/s00330-023-09547-7. Epub 2023 Apr 5.
3
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
4
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
5
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.
Zotero 插件